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Abstract. Introduction: Malignant pleural mesothelioma
(MPM) is a rare but highly aggressive malignancy most
often associated with exposure to asbestos. Recent evidence
points to oestrogen receptor (ER)-β having a tumour-
suppressor role in MPM progression, and this raises the
question of whether selective modulators of ERs could play
a role in augmenting MPM therapy. Materials and Methods:
We investigated the action of tamoxifen in inhibiting the
growth and modulating the cisplatin sensitivity of four MPM
cell lines. Results: Tamoxifen inhibited the growth of MPM
cells and also modulated their sensitivity to cisplatin. The
MPM cell lines expressed ERβ, but the actions of tamoxifen
were not blocked by antagonism of nuclear ERs. Tamoxifen
treatment repressed the expression of cyclins by MPM cells,
resulting in cell-cycle arrest and caspase-3-coupled
apoptosis signalling. Conclusion: The ER-independent
actions of tamoxifen on MPM cell proliferation and cell-
cycle progression may have clinical benefits for a subset of
patients with MPM.
Malignant pleural mesothelioma (MPM) is a rare neoplasm
arising from the mesothelial cells lining the thoracic cavity,
and is highly associated with exposure to asbestos (1). MPM
has a long latent period, with the malignancy developing
more than 30 years after exposure to the carcinogen, and an
extremely poor post-diagnosis median survival time of 9 to
12 months (2, 3). The preferred therapy for MPM is
determined by a number of factors, including age and
associated co-morbidities, but intervention is essentially
limited to surgery (extra-pleural pneumonectomy) and
chemotherapy (4). The chemotherapeutic drug of choice is
cisplatin but survival is enhanced when it is used in
combination with pemetrexed. The capacity for these
interventions to prolong life is highly variable and is
influenced by factors including the histological type and
tumour stage at diagnosis (5). 
There is a gender dichotomy in MPM survival that is at
least in part the result of circulating oestrogens acting
through the beta isoform of the oestrogen receptor (ERβ) to
attenuate MPM cell growth (6), indicating MPM as an
endocrine-responsive malignancy. Selective ER modulators,
including tamoxifen and fulvestrant (ICI 182,780), are
important therapeutic agents in the treatment of oestrogen-
sensitive cancer. The suppression of breast carcinoma cell
growth through ERα antagonism is an important facet of
first-line treatment for this malignancy. The question remains
as to whether ER modulation could play a role in novel
interventions for MPM. Two small phase II and phase III
clinical trials were performed to investigate whether post-
surgical adjuvant therapy using cisplatin in combination with
interferon-α and tamoxifen (CIT) had a patient survival
benefit (7, 8). The results of these trials were inconclusive
and the aim of the present study was to establish whether
tamoxifen affects MPM cell growth and sensitivity to
cisplatin. 
Materials and Methods
Cell culture. The REN, MPP-89, Msto-211H (Instituto Scientifico
Tumouri, Genoa, Italy), H2052 MCF-7 and MET5A (American
Type Culture Collection, Teddington, UK) cell lines were routinely
maintained as described previously (9). For experimental purposes,
cells were maintained in oestrogen-free medium for 24 h prior to
treatment (10). Cells were treated with vehicle control, tamoxifen
(100 nM to 10 μM) or cisplatin (100 nM to 50 μM) over a time over
a period of 72 h. MPM cell viability was measured after treatment
using the Cell-Titer 96 Assay (Promega, Southampton, UK).
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Synergistic effects of tamoxifen with cisplatin were investigated by
treating cells with tamoxifen (5 μM) before the addition of cisplatin
(0.1 μM to 50 μM) and then measuring viability. The involvement
of ERs in transducing the effects of tamoxifen were investigated by
pre-incubation with ICI182,780 (1 μM) or MPP (100 nM) before
tamoxifen treatment. 
Western blotting. MPM cells were incubated in oestrogen-free
medium for 24 h before the treatments indicated. Lysates were
prepared and subjected to sodium dodecylsulphate–polyacrylamide
gel electrophoresis and western blotting using standard techniques.
Following incubation with primary antibodies. All primary
antibodies were purchased from Cell Signaling Technology (Leiden,
The Netherlands) except for ERα and ERβ antibodies, which were
obtained from Leica Microsystems (Ashbourne, Ireland). Bound
antibodies were detected with horseradish peroxidase-conjugated
secondary antibodies (Sigma, Arklow, Ireland) and visualized using
the ECL+ detection system (GE Healthcare, Little Chalfont, UK). 
Quantitative polymerase chain reaction. Total RNA was extracted
from treated cells using the RNeasy extraction kit (Qiagen, Crawley,
UK). RNA was quantified and its purity measured using a
NanoDrop 8000 spectrophotometer (Eppendorf, Stevenage, UK).
Reverse transcription of isolated mRNA to synthesize cDNA was
performed using ImProm-II kit (Promega). Real-time (RT) PCR
using a 7500 Fast System and SYBR Green reagents (Applied
Biosystems, Warrington, UK) was used to quantify the abundance
of chosen mRNA species (Table I). The abundance of each of the
mRNA species was normalised against 18S rRNA and expressed as
a fold change relative to untreated cells. 
Immunohistochemistry. Eighty-nine cases of MPM were identified
from the archive of the Pathology Unit, Regional Hospital of
Mestre-Venice, Italy. Informed patient consent for access to tissue
was obtained according to local ethical regulations. The tissue
samples were taken following videothoracoscopy biopsy or from
resected surgical specimens, fixed in neutral formalin and embedded
in paraffin. Primary antibodies specific for ERα and ERβ were used
in this study and the immunohistochemistry parameters for each
antibody were initially optimized using a breast carcinoma tissue
microarray as described previously (11). Slides were counterstained
with haematoxylin. 
Apoptosis assays. Caspase-3 plays an important role in apoptosis by
cleaving key cellular proteins such as DNA-fragmentation factor and
poly (ADP-ribose) polymerase (PARP). Caspase-3 is initially present
as a 32 kDa precursor protein, which is recruited into active
heterodimeric complexes when cells undergo apoptosis (12).
Activated caspase-3 is composed of two subunits, p20 and p11,
which result from proteolytic processing of the 32-kDa precursor
during apoptosis. A second processing step involving the removal of
a pro-domain from the p20 subunit generates a p17 subunit. Caspase-
3 cleavage was evaluated by western blotting as described above. 
For lactose dehydrogenase (LDH) release assays, 3×103 cells per
well were plated in 96-well plates in phenol red-free RPMI-1640
containing 1% charcoal-stripped serum. Following overnight
incubation, cells were treated with different concentrations of
tamoxifen or with ethanol vehicle. Cell cytotoxicity was assessed
24 h and 48 h after treatment using the LDH Cytotoxicity Detection
Kit (Roche) according to the manufacturer’s instructions. 
Results
Cisplatin and tamoxifen effects on MPM cell growth. The
MPM cell lines were treated with tamoxifen over a
concentration range of 0 to 10 μM for up to 72 h. Cell
viability assays were performed at 24 h, 48 h and 72 h (Figure
1A). The four MPM cell lines had different sensitivities to
tamoxifen and only H2052 cells had a 50% inhibitory
concentration (IC50)<10 μM after 72 h. Phase-contrast
microscopy revealed that after 48 h treatment with 1 μM
tamoxifen (Figure 1B), the fibroblastic Msto-211H and H2052
cells showed a marked change in morphology including
shrinkage, irregular shape and condensed chromatin in the
nuclei. A higher tamoxifen concentration (5 μM) induced
elongated lamellipodia in both cell lines and cell detachment. 
The cisplatin sensitivity of the MPM cell lines was also
evaluated (Figure 2A). The Msto-211H cell line was the
most sensitive to cisplatin (IC50=3 μM); the MPP-89 cells
were the next highest in sensitivity (IC50=7.5 μM); while the
REN and H2052 cells were relatively insensitive to cisplatin
(IC50 >50 μM and IC50=45 μM respectively). 
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Table I. Primer pairs used in reverse transcription-polymerase chain reaction analysis.
Gene                                                                Forward primer                                                                    Reverse primer
                                                                                                                                                                       
18S/RNA18S1                                                  CGGCTACCACATCCAAGGAA                                       GCTGGAATTACCGCGGCT
ERα/ESR1                                                       CACATGAGTAACAAAGGCATGG                                 ATGAAGTAGAGC CCGCAGTG
ERβ/ESR2                                                        GTCAGGCATGCGAGTAACAA                                       GGGAGCCCTCTTTGCTTTTA
p14/CDKN2A                                                  CCCTCGTGCTGATGCTACTG                                         CATCATGACCTGGTCTTCTAGGAA
p15/CDKN2B                                                  GGGAAAGAAGGGAAGAGTGTCGTT                          GCATGCCCTTGTTCTCCTCG
p16/CDKN2A                                                  GGGGGCACCAGAGGCAGT                                           GGTTGTGGCGGGGGCAGT T
p21/CDKN1A                                                  GCATGACAGATTTCTACCACTCC                                 AAGATGTAGAGCGGGCCTTT
p27/CDKN1B                                                  CGCCATATTGGGCCACTAA                                           CGCAGAGCCGTGAGCAA
Cyclin A2/CCNA2                                           CTGCTGCTATGCTGTTAGCC                                         TGTTGGAGCAGCTAAGTCAAAA
Cyclin B1/CCNB1                                           ATAAGGCGAAGATCAACATGGC                                  TTTGTTACCAATGTCCCCAAGAG
Cyclin D1/CCND1                                          CTGGAGGTCTGCGAGGAA                                            GGGGATGGTCTCCTTCATCT
Cyclin D3/CCND3                                          GAGCTGCTGTGTTGCGAAG                                          GCATGTGCGGCTTGATCTC
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Figure 1. A: Cell-Titer 96 cell viability assays for REN, MPP-89, Msto-211H and H2052 malignant pleural mesothelioma (MPM) cells treated with
0 to 10 μM tamoxifen over a time course of 0 to 72 h. Data are the mean±SE of three independent experiments. B: Phase-contrast microscopy
images of MPM cells treated with tamoxifen over a concentration range of 0 to 5 μM for 48 h. Msto-211H (i-iii) and H2052 (iv-vi) cells were
treated with tamoxifen at 1 μM (ii and v), 5 μM (iii and vi) or vehicle (ethanol diluted in medium to the same concentration as the ethanol used to
initially dissolve tamoxifen); (i and iv). Representative images are shown at ×40 magnification. 
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Figure 2. Cell-Titer 96 cell viability assays for REN, MPP-89, Msto-211H and H2052 malignant pleural mesothelioma (MPM) cells treated with 0
to 50 μM tamoxifen over a time course of 0 to 72 h (A) or with cisplatin over a concentration range of 0 to 50 μM for 48 h in the presence or
absence of 5 μM tamoxifen (B). Data are the mean±SE of three independent experiments.
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Figure 3. A: Quantitative polymerase chain reaction analysis of oestrogen receptor (ER)-α and ERβ mRNA abundance in REN, MPP-89, Msto-
211H and H2052 malignant pleural mesothelioma (MPM) cells. Data presented are the mean of three independent experiments calculated as fold
difference relative to expression in MCF-7 breast cancer cells. B: Western blot analysis of ERα and ERβ expression by REN, MPP-89, Msto-211H,
H2052 MPM cells, MET-5A non-malignant mesothelial cells and MCF-7 breast carcinoma cells. Data are representative of two independent
experiments and glyceraldehyde-3 phosphate dehydrogenase (GAPDH) expression was used as an equal loading control. C: Detection of ERβ
expression by immunoperoxidase staining in normal pleural membrane (i) and in MPM tumour biopsies (ii-iv). The mages are representative of 89
tumour specimens examined. D: Cell viability assays for H2052 MPM cells treated with 0 to 10 μM tamoxifen in the presence or absence of MPP
(100 nM) or ICI 182,780 (1 μM) for 48 h. Data are the mean±SE of three independent experiments. 
We performed cell viability assays to establish whether
co-treatment with tamoxifen (5 μM) affected the sensitivity
of MPM cells to cisplatin treatment (Figure 2B). Each of the
cell lines displayed different responses. There was no effect
of tamoxifen co-treatment on the cisplatin sensitivity of
MPP-89 cells which is in agreement with this cell line
having the lowest sensitivity to tamoxifen (IC50=7.5 μM
with/without tamoxifen). Tamoxifen co-treatment was more
cytotoxic for REN cells at doses of cisplatin below 20 μM,
but tamoxifen suppressed sensitivity to cisplatin at
concentrations of >20 μM. The effect was more pronounced
for Msto-211H cells, where co-treatment with 5 μM
tamoxifen enhanced cytotoxicity at low doses of cisplatin
(<2.5 μM) but antagonized the action of cisplatin at higher
doses, suggesting that for this cell line, tamoxifen suppressed
sensitivity to high-dose cisplatin. H2052 cells were highly
sensitive to tamoxifen and there was an 80% loss of viability
at all cisplatin concentrations tested. Tamoxifen alone or in
combination with low doses of cisplatin may be effective in
reducing tumour growth in a subset of patients, but the
antagonistic action of tamoxifen at higher cisplatin
concentrations would be detrimental.
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Figure 4. A: Quantitative polymerase chain reaction (PCR) analysis of mRNA expression of p14, p15, p16, p21 and p27 cyclin-dependent kinase
inhibitors by H2052 malignant pleural mesothelioma (MPM) cells treated with tamoxifen (5 μM) or vehicle for 48 h. Data are the mean±SE of three
independent experiments. B: Western blot analysis of retinoblastoma protein (Rb), p27 and p21 expression by Msto-211H and H2052 cells following
treatment with 0 to 5 μM tamoxifen for 48 h. Data are representative of two independent experiments and glyceraldehyde-3 phosphate dehydrogenase
(GAPDH) expression was used as an equal loading control. C: Quantitative PCR analysis of cyclin A2, cyclin B1, cyclin D1 and cyclin D3 mRNA
expression by H2052 MPM cells treated with tamoxifen (5 μM) or vehicle for 48 h. Data are the mean±SE of three independent experiments calculated
as fold change relative to vehicle-treated cells. D: Western blot analysis of cyclin A2, cyclin B1, cyclin D1, cyclin D2, cyclin D3, cyclin E1 and cyclin
E2 expression by Msto-211H and H2052 MPM cells following treatment with 0 to 5 μM tamoxifen for 48 h. Data presented are representative of two
independent experiments and GAPDH expression was used as an equal loading control. Significantly different at *p<0.05, and **p<0.01.
The action of tamoxifen on MPM cell growth is ER-
independent. ERα mRNA was not expressed in REN, MPP-
89 or Msto-211H cell lines but was detectable in H2052 cells
(Figure 3A). ERβ mRNA was variably expressed by all four
of the cell lines at a comparable abundance with that of the
MCF-7 cells. ERα protein was detectable in H2502 cells but
only after overexposure of the western blot, and was absent
from the other three MPM cell lines (Figure 3B). ERβ
protein was variably expressed in all of the cell lines,
consistent with the quantitative PCR data. ERβ abundance
varied between the 89 individual tumour specimens, with
high levels of expression observed in normal mesothelial
cells (Figure 3Ci), and very high to negative expression in
the tumour samples (Figure 3Cii-iv). ERα expression was
not detected in any of the specimens (data not shown). ER
involvement in MPM growth inhibition by tamoxifen was
investigated using specific ER antagonists. ERα antagonism
using MPP (100 nM) had no effect on H2052 MPM cell-
growth inhibition by tamoxifen (Figure 3D). ICI182,780 is
a highly specific antagonist for both ERα and ERβ, with no
agonist activity. ICI182,780 (1 μM) co-treatment did not
attenuate the effects of tamoxifen on H2052 MPM cell
growth. 
The effect of tamoxifen on cyclin-dependent kinase (CDK)
inhibitor and cyclin expression. H2052 cells were most
sensitive to tamoxifen and were therefore used to determine
if tamoxifen affects CDK inhibitor expression in MPM cells.
The cells were treated with 5 μM tamoxifen for 48 h and RT-
PCR was carried out to measure p14, p15, p16, p21 and p27
mRNA abundance (Figure 4A). There was no detectable p14,
p15 or p16 expression in H2052 cells and this was not
affected by tamoxifen treatment. The expression of p21 and
p27 was detected in H2052 cells but the abundance of
mRNA (Figure 1A) and protein (Figure 4B) was not affected
by tamoxifen treatment. 
Cyclins are pivotal in regulating cell-cycle progression
and are overexpressed in many malignancies. Quantitative
PCR was used to measure cyclin A2, cyclin B1, cyclin D1
and cyclin D3 mRNA abundance following the tamoxifen
Jennings et al: Tamoxifen and Cisplatin Sensitivity of Mesothelioma
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Figure 5. A: Measurement of lactate dehydrogenase release by Msto-
211H and H2052 MPM cells over 48 h following treatment with
tamoxifen at 0 to 10 μM. Data are the mean±SE of three independent
experiments as calculated as the percentage cytotoxicity relative to
vehicle-treated cells. B: Western blot for caspase-3 expression and
proteolytic activation in H2052 cells treated with 0 to 5 μM tamoxifen
for 48 h. Data are representative of two independent experiments and
glyceraldehyde-3 phosphate dehydrogenase (GAPDH) expression was
used as an equal loading control.
treatment (5 μM) of H2052 cells for 48 h (Figure 4C).
Tamoxifen treatment caused a significant reduction in the
abundance of cyclin A2, cyclin B1, cyclin D1 and cyclin D3
mRNA in H2052 cells. These transcriptional changes
following tamoxifen treatment were mirrored by changes in
the abundance of the cyclin proteins as determined by
western blotting (Figure 4D). Cyclin A2 was reduced on
treatment at a concentration of 5 μM tamoxifen in H2052
cells, however, no significant reduction was observed in
Msto-211H cells. Cyclin B1 protein expression was reduced
in both Msto-211H and H2052 cells, with the greatest
reduction observed at the highest concentration of tamoxifen.
Cyclin D1 and cyclin D3 protein expression levels were
reduced in both Msto-211H and H2052 cells following
tamoxifen treatment; however, no changes in cyclin D2
protein expression levels were observed. Both cyclin E1 and
cyclin E2 were also reduced following tamoxifen treatment
in Msto-211H and H2052 cells. 
Tamoxifen promotes apoptosis of MPM cells. Tamoxifen at
concentrations of >1 μM had significant effects on the
morphology of MPM cells (Figure 1B) and these
morphological changes were consistent with apoptosis or
necrosis. LDH assays were performed to evaluate the direct
cytotoxicity of tamoxifen on MPM cells. LDH release is a
marker of cytotoxicity and is associated with cell membrane
disintegration. Tamoxifen treatment caused the dose-
dependent release of LDH from both Msto-211H and H2052
cells (Figure 5A). H2052 cells were treated with tamoxifen
over a concentration range of 0.1 to 5 μM for 48 h and the
abundance and proteolytic activation of caspase-3 was
evaluated by western blotting (Figure 5B). Tamoxifen
treatment did not affect the abundance of pro-caspase -3 but
a tamoxifen concentration as low as 1 μM did increase the
abundance of the activated caspase-3 p17 and p11 subunits,
indicating that tamoxifen stimulated apoptosis of H2052 cells. 
Discussion
MPM cells either do not express ERα or its abundance is
extremely low in the case of the H2052 cells, and the
mechanisms that transduce tamoxifen action independently
of ERα activation in other experimental systems are
controversial (13, 14). Tamoxifen inhibits the survival of
other tumour cell types via diverse ER-independent
mechanisms, including modulation of the action of
transforming growth factor (TGF)-β and c-MYC activation
of Janus kinase signalling, enhanced oxidative stress,
increased ceramide generation, and alterations in
mitochondrial permeability transition (15). Tamoxifen
inhibits cellular proliferation in a variety of tissue and cancer
types through up-regulation of CDK inhibitors such as p15
(16), p16 (17), p21 (16, 17) and p27 (18). The activation of
ERβ by oestrogen suppresses MPM cell growth by
mechanisms which include the transcriptional regulation of
CDK inhibitors (6). Data from our present study indicate that
tamoxifen acts through different mechanisms that modulate
the expression of cyclins rather than CDK inhibitors, and
that this suppression in cyclin expression is ERβ-
independent.
Tamoxifen treatment induces apoptosis of breast cancer
cells (19), cholangiocarcinoma cells (20) and
rhabdomyosarcoma cells (21) at least in part through induction
of caspase-3 activity. The stimulation of apoptosis by
tamoxifen has been described in a number of tissues and
pathological conditions. Various mechanisms have been
ascribed to these actions including calmodulin antagonism, c-
MYC induction, protein kinase C activation, caspase-3
activation and TGFβ induction [reviewed in (15). In the
present study, we found that tamoxifen treatment
simultaneously induced apoptosis and cell-cycle arrest in
MPM cells. In common with our observations for MPM,
tamoxifen induced cell death in malignant peripheral nerve
sheath tumours at <5 μM and inhibited mitosis at <1 μM;
these effects were independent of nuclear ER, but were
mimicked by direct calmodulin inhibition (22). The interaction
of calmodulin with other effector proteins is modulated by the
availability of intracellular Ca2+, and the dysregulation of
intracellular Ca2+ homeostasis has also been attributed to ER-
independent actions of tamoxifen on breast cancer cells (23).
In conclusion, the growth-inhibitory effect of tamoxifen
on MPM cells is achieved through the suppression of cyclin
expression and the induction of caspase-3 activation via ER-
independent mechanisms. Tamoxifen may have potential as
a therapeutic agent in the treatment of MPM; however, its
use in combination therapies may be compromised by its
effects on slowing cell-cycle progression, which renders
MPM cells less sensitive to platinum-based chemotherapy.
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